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ABSTRACT
Objectives: In the Gambia, chloroquine (CQ) plus sulphadoxine-pyrimethamine (SP) is the
first-line antimalarial treatment. Plasmodium falciparum parasites carrying mutations associated
with resistance to each of these drugs were present in 2001 but did not cause a significant loss
of therapeutic efficacy among children receiving the combination CQ/SP. We measured their
effect on parasite transmission to Anopheles gambiae mosquitoes.
Design: We conducted a single-blind, randomised, controlled trial with follow-up over 28 d.
Mosquito feeding experiments were carried out 7, 10, or 14 d after treatment.
Setting: The study took place in the town of Farafenni and surrounding villages in the
Gambia.
Participants: Participants were 500 children aged 6 mo to 10 y with uncomplicated P.
falciparum malaria.
Interventions: Children were randomised to receive CQ, SP, or CQ/SP.
Outcome Measures: Outcomes related to transmission were determined, including
posttreatment gametocyte prevalence and density. Infectiousness was assessed by mem-
brane-feeding A. gambiae mosquitoes with blood from 70 gametocyte-positive patients.
Mutations at seven loci in four genes associated with drug resistance were measured pre- and
posttreatment and in the midguts of infected mosquitoes.
Results: After SP treatment, the infectiousness of gametocytes was delayed, compared to the
other two treatment groups, despite comparable gametocyte densities. Among bloodmeal
gametocytes and the midguts of infected mosquitoes, the presence of the four-locus
multidrug-resistant haplotype TYRG (consisting of mutations pfcrt-76T, pfmdr1-86Y, pfdhfr-59R,
and pfdhps-437G) was associated with significantly higher oocyst burdens after treatment with
the combination CQ/SP.
Conclusions: Parasites with a multidrug-resistant genotype had a substantial transmission
advantage after CQ/SP treatment but did not have a significant impact on in vivo efficacy of
this drug combination. Protocols that include measuring transmission endpoints as well as
therapeutic outcomes may be a useful strategy when monitoring the evolution of drug
resistance in malaria parasites in vivo.
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PLoS CLINICAL TRIALSINTRODUCTION
The widespread occurrence of drug-resistant parasites in
malaria endemic regions has led to rapid changes in
antimalarial treatment policies in many countries. In some
parts of Southeast Asia, multidrug-resistant parasites are
prevalent and have greatly reduced the efﬁcacy of the
majority of monotherapy regimens. This has led to the
implementation of combination therapies, including artemi-
sinin-based treatment throughout the region [1]. In sub-
Saharan Africa, monotherapies such as chloroquine (CQ) and
the antifolate ﬁxed combination sulphadoxine-pyrimeth-
amine (SP) have continued to be widely used. Parasites
resistant to CQ are common and known to contribute to
excess severe malaria cases [2], and SP-resistant genotypes
have spread widely across the continent from a few focal
origins [3]. Thus, despite there being few studies of multi-
drug-resistant Plasmodium falciparum in Africa, it is likely that
parasites harbouring mutations conferring resistance to both
CQ and SP circulate in many areas. Policy changes towards
the implementation of artemisinin-containing combination
therapies (ACTs) are now occurring in many countries [4].
One of the potential beneﬁts of ACT use is that the
artemisinincomponenthasthedemonstratedabilitytoreduce
gametocyte carriage and thus transmission to mosquitoes [5].
Other antimalarial drugs vary in their effect on gametocytes;
CQ and other 4-aminoquinolines exert their effect on the
parasite’shaem-metabolisingstages,whichincludesearly-stage
gametocytes. In contrast, antifolates such as SP are only
effective during asexual development and will not affect
parasites once these are committed to the sexual pathway [6].
The implementation of ACTs is costly and is currently
beset with problems of supply due to the very rapid
expansion in demand for artemisinin drugs in the last few
years. Therefore, some African Ministries of Health have
moved to combinations of established antimalarials as a ﬁrst
step away from monotherapies, in anticipation of a second
switch to ACTs as soon as it is feasible. Senegal has
implemented SP plus amodiaquine as ﬁrst-line replacement
for CQ monotherapy, with a move to amodiaquine plus
artesunate planned for 2006. In the Gambia, where CQ
monotherapy is no longer efﬁcacious [7], it has been replaced
by CQ combined with SP (CQ/SP), with the longer-term goal
being implementation of ACT.
Earlier studies in the Gambia had shown that CQ plus SP
was as efﬁcacious as SP alone as treatment for uncomplicated
malaria in children and was more effective at providing rapid
symptomatic relief [8]. However, in studies of the infectious-
ness to mosquitoes of treated Gambian children with
uncomplicated falciparum malaria, we have found that SP
and CQ both permit substantial transmission during the ﬁrst
week following treatment [9,10] as does the combination CQ/
SP [11]. CQ-resistant parasites were already highly prevalent
in the Farafenni area when these studies were carried out and
displayed enhanced gametocyte carriage and higher intensity
of mosquito infection than wild-type parasites in CQ-treated
individuals [12,13]. Furthermore, we have shown that mutant
forms of the pfdhfr and pfdhps loci associated with SP
resistance and carriage of gametocytes after SP treatment
[14] were also common [15]. We were concerned therefore
that the combination CQ/SP would selectively enhance the
transmission and circulation of multidrug-resistant parasites.
Such an enhancement may persist for some time after
treatment, given the long half-life of SP, and the longevity
of P. falciparum gametocytes.
In 2001, we conducted a single-blind, randomised, controlled
trial of CQ versus SP versus CQ/SP in Gambian children aged 6
mo to 10 y presenting to Farafenni Hospital with uncompli-
cated P. falciparum malaria. We report in the accompanying
paper [15] the therapeutic efﬁcacy of the regimens used, and
the identiﬁcation of a four-locus parasite genotype that was
associated with treatment failure and may represent a multi-
drug-resistant phenotype in the Gambia. Posttreatment game-
tocyte carriage and infectiousness of gametocyte carriers to
mosquitoes are examined here. We also evaluated the
contribution of parasites carrying a multidrug-resistant geno-
type to transmission success in each treatment group.
METHODS
The study was a single-blind, randomised, controlled trial to
compare efﬁcacy of treatment of children with uncompli-
Editorial Commentary
Background: In an accompanying paper published in PLoS Clinical Trials
[15], the investigators report the effects of treating uncomplicated
malaria in young children in the Gambia with the combination of
chloroquine and sulfadoxine-pyrimethamine, as compared to either
treatment individually. As an addition to the main trial results, the
researchers also wanted to find out how the different treatment
regimens affected the ability of the malaria parasite to generate sexual
forms (gametocytes) in the participants’ blood, and to what extent the
parasites are then transmitted to mosquitoes. The researchers also tested
whether malaria parasites had a specific genotype, termed TYRG,
comprising mutations in four distinct genes associated with resistance to
chloroquine and sulfadoxine-pyrimethamine, and whether that affected
transmission of the parasites back to mosquitoes.
What the trial shows: In this trial it was found that children treated with
chloroquineandsulfadoxine-pyrimethaminewerenomoreorlesslikelyto
carry sexual forms of the malaria parasite compared to children treated
with chloroquine, over 28 days of follow-up. Transmission of the malaria
parasites back to mosquitoes also did not differ significantly between
children treated with chloroquine and sulfadoxine-pyrimethamine versus
chloroquine alone. Parasites bearing the TYRG genotype, associated with
drug resistance, were more likely to be transmitted to mosquitoes from
children treated with chloroquine/sulfadoxine-pyrimethamine than from
chloroquine treated children.
Strengths and limitations: The addition of data about parasite
transmission within the setting of a randomized trial is valuable and can
provide information about the evolution of drug resistance. However,
the results may not completely represent the current situation, as the
trial was originally conducted in 2001 and levels of resistance may now
be higher in the Gambia.
Contribution to the evidence: This follow-up study to a randomized
trial provides additional evidence that treatment with chloroquine and
sulfadoxine-pyrimethamine, as compared to chloroquine, does not
reduce the extent to which malaria parasites can produce sexual forms
and transmit them back to mosquitoes. The finding that parasites
bearing the TYRG genotype are more likely than other parasites to be
transmitted back to mosquitoes following chloroquine and sulfadoxine-
pyrimethamine treatment is also novel.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.
www.plosclinicaltrials.org July | 2006 | e15 0002
Transmission of Drug-Resistant Malariacated P. falciparum malaria with CQ, SP, or CQ/SP. Full details
of the participants and interventions are described in the
accompanying paper [15].
Objectives
The primary objectives were to measure posttreatment
gametocyte prevalence and density in each of the three
treatment groups and to assess how this related to infectious-
ness to mosquitoes. Within the SP group, the effect of time
after treatment was also examined, because gametocyte
samples were collected on three different follow-up days.
Secondary measurements included the contribution of genet-
ically deﬁned drug-resistant parasites to mosquito oocyst
burden and the effect of drug group on transmission success.
Outcomes
Outcomes measured were gametocyte carriage and density on
deﬁned follow-up days, and the proportion of mosquitoes
infected. The number of oocysts was counted in each infected
mosquito midgut. For all infections used for mosquito
feeding, the genotype at drug resistance-associated loci was
determined at three time points: pretreatment, and post-
treatment in the gametocyte-positive blood feed sample and
in the mosquito midguts arising from successful infections.
Sample Size and Randomisation
The sample size, randomisation, and blinding are described
in the accompanying paper [15].
Posttreatment Follow-Up
Follow-up procedures relating to efﬁcacy endpoints are
described in the accompanying paper [15]. In order to fulﬁll
the transmission objectives, children were collected from
their homes either on day 7, 10, or 14 after treatment and
taken to the Medical Research Council Field Station in
Farafenni, where they were clinically examined and ﬁnger
prick blood samples were obtained for thick blood ﬁlm
preparation and packed cell volume estimation. The blood
ﬁlms were stained with Field’s stain and examined immedi-
ately for malaria parasites. Children with gametocytes were
requested to provide 3.0 ml of venous blood for mosquito
infectivity experiments as previously described [9,10]. For
those who had received CQ or CQ/SP, this happened on day 7
only. Among the SP-treated group, children were assigned a
gametocyte screening day according to the day of the week
they were recruited to overcome the logistical problems that
would be caused by a nested second randomisation. Thursday
and Friday recruits receiving SP were screened for game-
tocytes on day 7, Tuesday and Saturday recruits were
screened on day 10, and Monday and Wednesday recruits
were screened on day 14. Recruiting did not occur on
Sundays. SP-treated children who were screened on day 10 or
14 were not visited on day 7 and therefore were not subject to
follow-up equivalent to that of SP-treated children screened
on day 7 or of children in the other treatment groups, all of
whom were screened on day 7.
Membrane-Feeding and Mosquito Dissection
Venous blood samples were obtained from children with a
packed cell volume of .20%, who had been free of peripheral
gametocytes at the time of recruitment (day 0) but who were
gametocytaemic (limit of detection, 5 gametocytes/ll) when
screened on day 7, 10, or 14. Speciﬁc consent for the
procedure was obtained from the parents or guardians. If no
children fulﬁlling these criteria were available as donors but
cages of mosquitoes had been prepared, children who had
been gametocyte positive on day 0 were selected. Membrane-
feeding was performed as described elsewhere [9,10]. In brief,
venous blood in citrate-phosphate dextrose was centrifuged,
and the plasma was removed. After being washed, the red
blood cell pellet was split into two aliquots of 300–500 ll each.
These were resuspended to a packed cell volume of 33% in,
respectively, the original autologous plasma and in pooled AB
serum from European donors with no history of malaria
exposure (control serum). Each suspension was then fed to
approximately 50 3- to 5-d-old female Anopheles gambiae
mosquitoes (obtained as F1 progeny of wild-caught gravid
females) via an artiﬁcial membrane attached to a water-
jacketed glass feeder maintained at 37 8C. Mosquito midguts
were dissected out 7–8 d later, and the number of malaria
oocysts on each one was recorded. Each oocyst-positive
midgut was retained in a separate tube of 95% ethanol.
Parasite Genotyping
DNA was extracted from day 0 bloodspots on ﬁlter paper and
from the remainder of the venous blood sample taken for
membrane-feeding by boiling with chelex-100 [16]. Oocyst
DNA was obtained from infected mosquito midguts as
follows: each sample was rehydrated in 500 ll of a 1:1 mix
of ethanol and TE buffer (10 mM Tris-HCl, 1 mM EDTA)
before being incubated at 56 8C overnight in 200 llo f6 %
chelex containing 20 lg of proteinase K. Samples were then
boiled for 30 min and 5 ll of the supernatant was used in PCR
ampliﬁcations [17].
A sequence-speciﬁc oligonucleotide probing assay was used
to detect polymorphisms at loci associated with CQ and SP
resistance in all PCR-positive DNA extracts [12,18]. These
were pfcrt-K76T, pfmdr1-N86Y, pfmdr1-Y184F (linked to CQ
resistance), and pfdhfr-N51I, pfdhfr-C59R, pfdhfr-S108N, pfdhps-
A437G, and pfdhps-K540E (linked to SP resistance). For some
analyses, where mixtures of drug-sensitive and drug-resistant
parasites were detected, they were scored as resistant to
reﬂect the expected phenotype of the infection.
Statistical Methods
All data were double entered and veriﬁed using Epi-Info,
version 6 (Centers for Disease Control and Prevention,
Atlanta, Georgia, United States). Clinical, parasitological,
and entomological data entered in Epi-Info were transferred
to Stata 8.1 (Stata Corporation, College Station, Texas,
United States) for statistical analysis. Categorical variables
were compared among groups using odds ratios and
signiﬁcance tested by the Fisher exact test. Gametocyte
densities counted in thick ﬁlms and oocyst density on
mosquito midguts were compared between treatment groups
in pairwise fashion. The ratio of the arithmetic means was
calculated, and generalized linear models with a logarithmic
link function and negative binomial distribution family were
ﬁtted to the data. This models the logarithm of the
(arithmetic) mean gametocyte density, or oocyst density as
previously described [10,11]. Ratios of mean densities were
obtained by exponentiating the relevant regression coefﬁ-
cients. Oocyst data were corrected for clustering within
mosquito cages fed on blood from the same individual.
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Participant Flow
A total of 500 eligible patients were enrolled into the trial, as
described in detail elsewhere [15]. After allocation to treat-
ment groups, 193, 181, and 126 children were treated with
CQ/SP, SP, and CQ, respectively. Among the SP-treated
group, 79, 40, and 62 children were scheduled for gametocyte
screening on days 7, 10, and 14, respectively. A trial proﬁle is
presented in Figure 1, and clinical and parasitological
outcomes are presented in the accompanying paper [15].
Gametocyte Prevalence and Density
The prevalence of posttreatment gametocyte carriage at each
day of follow-up among children without gametocytes at
presentation is shown in Figure 2. Approximately 20% of
children in each treatment group were gametocyte-positive at
day 0. This is consistent with our previous ﬁndings [10]. These
children, who had a 90% chance of carrying gametocytes at
some point during follow-up after treatment (data not
shown), are omitted from prevalence estimates at subsequent
time points. In pairwise comparisons, there was no signiﬁcant
difference in gametocyte carriage between the CQ and CQ/SP
treatment groups at day 3 (p ¼ 0.71), day 7 (p ¼ 0.066), day 14
(p¼0.82), or day 28 (p¼0.26). In contrast, SP-treated children
were signiﬁcantly more likely to become gametocyte carriers
than were CQ/SP-treated or CQ-treated children at day 3 (p¼
0.009, 0.054, respectively), day 7 (p ¼ 0.002, , 0.001), and day
14 (p , 0.001 in both cases), but not at day 28 (p¼0.089, 0.66).
Gametocyte carriage in the CQ treatment group was closely
associated with treatment failure, as previously observed in
this population [10,12]. Gametocyte carriage during follow-
up was observed in 14 of 39 children (35.9%) presenting free
of gametocytes and successfully treated with CQ, compared to
40 of 53 children (75.5%) who carried P. falciparum troph-
ozoites at any point during the 28 d of follow-up (odds ratio,
5.17; 95% conﬁdence interval [CI], 1.95–13.9; p , 0.0001).
This was not seen in either of the other treatment groups,
which were both highly efﬁcacious [15].
A pairwise comparison of mean gametocyte density
between treatment groups at each time point was carried
out, including all evaluable children who were not game-
tocyte carriers at presentation. Gametocyte density in the SP-
treated group was signiﬁcantly higher than in the CQ/SP
group at days 7, 14, and 28 (ratio of means, 3.06 [p ¼ 0.031],
3.68 [p ¼ 0.001], and 31.2 [p , 0.001], respectively).
Gametocyte density in the CQ/SP-treated group was higher
than in the CQ group at day 3 (ratio of means, 3.76 [p ¼
0.046]), but there was no signiﬁcant difference between these
two groups at day 7 (ratio of means, 1.73 [p¼0.30]) or day 14
(ratio of means, 1.69 [p¼0.25]). At day 28, gametocyte density
in the CQ/SP-treated group was signiﬁcantly lower than in the
CQ group (ratio of means, 0.111 [p ¼ 0.001]).
Infectiousness of Gametocyte Carriers
Venous blood was donated by 72 gametocyte carriers for
membrane-feeding, resulting in 70 evaluable feeding experi-
ments, and the dissection of 2033 blood-fed adult female
mosquitoes. Results of the feeding experiments in both
autologousplasmaandcontrolserumarepresentedinTable1.
As a measure of infectiousness, the mean number of
oocysts per infected midgut was compared among treatment
groups and across different feed days in the SP-treated group
Figure 2. Prevalence and Positive Arithmetic Mean Density of
Gametocytes in Treated Children
Those carrying gametocytes at day 0 were excluded from the denominator at
subsequent follow-up days (see data table). Bars represent prevalence of
gametocyte carriage, with error bars showing 95% CIs. Lines represent
arithmetic mean gametocyte density in carriers only.
DOI: 10.1371/journal.pctr.0010015.g002
Figure 1. CONSORT Flowchart
A total of 1,366 children was screened, and 500 were randomised. Children
randomised to receive SP were scheduled for gametocyte screening on day 7,
10, or 14 (see text). Shaded boxes represent gametocyte screening days. Loss
to follow-up is detailed in the main trial paper [15].
DOI: 10.1371/journal.pctr.0010015.g001
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Transmission of Drug-Resistant Malaria(Figure 3 and Table 2). In regression analysis, the mean oocyst
burden did not differ signiﬁcantly between the CQ and CQ/
SP groups (data not shown). Among SP-treated donors, those
identiﬁed 10 or 14 d after treatment were signiﬁcantly more
infectious than were day 7 donors (p ¼ 0.008, p ¼ 0.020
respectively), despite high gametocyte densities in the latter
group (Figure 3 and Table 2).
When we compared SP-treated children who carried
gametocytes on day 0 with those who did not, signiﬁcantly
greater infectiousness in day 10 and 14 gametocyte carriers
was seen only among those with gametocytes at presentation
(Table 2). There is therefore an important contribution of
gametocyte maturity to infectivity.
Contribution of Resistant Genotypes to Circulating
Gametocyte Populations
We report elsewhere on the prevalence of resistance-
associated parasite genotypes in the study population, and
the contribution of such parasites to treatment failure [15]. It
was found that multidrug-resistant parasites exempliﬁed by
the four-allele genotype TYRG (i.e., simultaneous carriage of
pfcrt-76T, pfmdr1-86Y, pfdhfr-59R, pfdhps-437G) were contribu-
ting signiﬁcantly to parasitological failure after treatment
with SP. Parasites with the TYRG genotype were also present
in some cases after treatment with CQ/SP and thus likely to be
selected with widespread combination drug pressure. We
therefore tested for associations between either posttreat-
ment gametocyte emergence or transmission success and
resistance-associated alleles at seven loci alone and in
combination.
Carriage of genetically resistant parasites at presentation
was associated with the presence of gametocytes during the
follow-up period, as shown in Figure 4. Gametocyte donors
carried higher pretreatment prevalences of CQ and SP
resistance-associated markers than a random sample of the
trial population who had remained gametocyte negative. This
increase was signiﬁcant for the CQ resistance markers pfcrt-
76T and pfmdr1-86Y, but not for pfmdr1-184F. Similarly, the
difference was signiﬁcant when analysing the pyrimethamine-
resistant mutations in the pfdhfr gene (codons 51, 59, and 108)
both individually and together as presence of the ‘‘triple
mutant.’’ Pfdhps-437G was the only sulphadoxine-resistant
mutation detected in this population, and was found at a
higher prevalence in gametocyte donors at day 0, but this
difference was not signiﬁcant. When grouping mutations into
the multidrug resistance-associated genotype TYRG as
deﬁned in Dunyo et al. [15] we found that this combination
of mutations showed an association with posttreatment
gametocytaemia (odds ratio, 3.0; 95% CI, 0.78–17.0; two-
sided Fisher exact, p ¼ 0.11), although this was also not
statistically signiﬁcant.
Selection of Drug Resistance Markers among
Gametocyte Donors
We have previously presented evidence of within-host direc-
tional selection from pfcrt-76K to T after CQ treatment [13].
However, in the current dataset, too few genotype changes
occurred between recruitment and mosquito-feeding to
perform this analysis for any of the loci examined. Resistance
markers were highly prevalent in presentation samples and,
in general, genotypes detected in gametocyte-positive feed
samples and in resulting oocysts reﬂected what was present at
day 0 (Table S1).
In two feeds (MF27 and MF40), mixed infections were
detected in some midguts, but not others, at the pfdhfr and
pfdhps-437 sites examined. In one further feed (MF59), six of
seven infected midguts carried pfmdr1-184F and one had
pfmdr1-184Y. In all other cases where multiple oocyst-positive
midguts arose from a single feed, they contained identical
parasite genotypes (Table S1).
The most infectious gametocyte sample (MF68) originated
from a CQ/SP-treated patient, producing 13 infected midguts
with a mean of 42 oocysts on each (range, 2–100). Eleven of
the 13 midguts were PCR-positive for all four resistance-
associated genes. CQR alleles pfcrt-76T, pfmdr1-86Y, and
pfmdr1-184F were detected pre- and posttreatment and in
all 11 midguts. The pfdhfr genotype was mixed with both wild-
type and resistance-associated alleles detected at positions 51,
59, and 108 both pre- and posttreatment. However, none of
.......................................................................................................................................................................................
Table 1. Results of Membrane-Feeding Experiments
Drug
Group
Feed
Day
Number
donors
Number Donors
Infectious
(Proportion)
Proportion Mosquitoes
Infected from Control
Serum Feeds (Frequency/N)
Proportion Mosquitoes
Infected from Autologous
Plasma Feeds (Frequency/N)
CQ 7 16 7 (43.8%) 4.2% (11/264) 2.6% (5/194)
CQ/SP 7 21 7 (33.3%) 8.7% (25/287) 4.8% (13/269)
SP 7 11 4 (36.4%) 2.1% (3/146) 1.5% (2/135)
10 10 3 (30.0%) 4.0% (6/149) 3.6% (5/138)
14 12 5 (41.7%) 2.8% (7/247) 3.4% (7/204)
DOI: 10.1371/journal.pctr.0010015.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 3. Relationship between Gametocyte Density and Oocyst Burden
in Feed Samples
DOI: 10.1371/journal.pctr.0010015.g003
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Transmission of Drug-Resistant Malariathese wild-type alleles were detected in the resulting 11
midguts, all of which harboured pure pfdhfr triple mutants
(51-I, 59-R, and 108-N).
Do Resistant Infections at Day 0 Contribute More to
Later Transmission?
Very few changes in parasite genotype at resistance-associ-
ated loci were observed from pretreatment sampling to
identiﬁcation of markers in infected mosquito midguts.
Therefore, we used day 0 data to look for associations
between multidrug-resistant genotypes and mean oocyst
count in mosquitoes membrane-fed on posttreatment emer-
gent gametocytes (i.e., considering only those subjects without
gametocytes at time of treatment). The presence of parasites
with the four-locus multidrug-resistant genotype TYRG at
day 0 was associated with higher oocyst numbers in SP and
.......................................................................................................................................................................................
Table 2. Mean Oocyst Densities after Feeds from All Gametocyte Carriers at d 7 after Treatment, and in SP-Treated Carriers at Days
10 and 14
Drug
Group
Day of
Gametocyte
Donation
All Midguts Stratified by d 0 Gametocyte Presence
All Gametocyte Donors
(N ¼1,019 Midguts)
Gametocyte Positive on
d0( N ¼ 299 Midguts)
Gametocyte Negative on
d0( N ¼ 720 Midguts)
Mean Oocyst
Density
(95% CI)
Ratio of Means,
Compared to
SP d 7 Feed
(95% CI)
Mean Oocyst
Density
(95% CI)
Ratio of Means,
Compared to
SP d 7 Feed
(95% CI)
Mean Oocyst
Density
(95% CI)
Ratio of Means,
Compared to
SP d 7 Feed
(95% CI)
CQ 7 0.769
(0.114–1.42)
27.9
(4.79–162)
p , 0.001
0.025
( 0.024–0.074)
0.994
(0.171–5.76)
p ¼ 0.994
1.17
(0.164–2.18)
41.8
(6.34–275)
p , 0.001
CQ/SP 7 1.10
(0.432–1.78)
40.1
(5.51–291)
p , 0.001
5.25
(1.77–8.73)
210
(35.0–1258)
p , 0.001
0.140
(0.068–0.211)
4.98
(1.18–21.1)
p ¼ 0.029
SP 7 0.0275
( 0.006–0.061)
Ref. 1.00 0.025
( 0.026–0.076)
Ref. 1.00 0.028
( 0.011–0.067)
Ref. 1.00
10 0.302
( 0.044–0.649)
11.0
(1.86–64.6)
p ¼ 0.008
1.12
( 0.431–2.68)
44.9
(17.2–117)
p , 0.001
0.066
(0.011–0.122)
2.37
(0.429–13.1)
p ¼ 0.323
14 0.207 (0.026–0.388) 7.50
(1.37–41.1)
p ¼ 0.020
0.490
(0.049–0.930)
19.6
(5.30–72.4)
p , 0.001
0.011
( 0.005–0.026)
0.38
(0.046–3.19)
p ¼ 0.374
The ratio of the means was calculated as the mean oocyst density in each group compared to that resulting from SP-treated carriers at day 7. Columns 5–8 show an additional
stratification by gametocyte carriage at presentation. Cells in blue denote reference measure for calculation of ratios. Statistically significant probabilities are shown in boldface.
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Figure 4. Contribution of Resistance-Associated Parasite Genotypes at Day 0 to Subsequent Gametocyte Emergence
Only subjects free of circulating gametocytes at enrollment are included. Pretreatment genotype data were obtained for 27 patients who remained gametocyte-
free during follow-up (white bars) and 46 patients with emergent gametocytes (grey bars). Pretreatment genotype prevalences for 47 gametocyte feed donors
are shown by the black bars. * indicates a significantly higher prevalence of the designated genotype than among the baseline nongametocyte carriage at
presentation.
DOI: 10.1371/journal.pctr.0010015.g004
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Transmission of Drug-Resistant MalariaCQ/SP groups, but this was not statistically signiﬁcant in
either group (for SP, N ¼ 644 dissected mosquitoes: mean
ratio, 4.14; 95% CI, 0.722–23.8; p¼0.111; for CQ/SP, N¼415:
mean ratio, 5.53; 95% CI, 0.742–41.2; p ¼ 0.095). In contrast,
in the CQ group, only one donor harboured TYRG parasites
at day 0, and there was no transmission from this child’s
gametocytes. Parasites carrying CQ resistance markers at pfcrt
and pfmdr1 without accompanying antifolate resistance
mutations in pfdhfr and pfdhps were highly transmissible in
the CQ group (N¼186; mean oocyst ratio: 261; 95% CI, 24.8–
2736; p , 0.001). This is consistent with previous ﬁndings [13].
Gametocyte and Oocyst Genotypes Impact
Significantly on Transmission Success
An unambiguous four-locus genotype could be assigned to
gametocyte feed samples from 56 children. Where mixed
infections were detected, these were scored as resistant.
Fourteen of the 56 were from children who had harboured
gametocytes at the time of treatment; four, eight, and two
children from the CQ, SP and CQ/SP treatment groups,
respectively. We analysed the contribution of TYRG parasites
to transmission in the 1680 mosquitoes that had fed on these
56 gametocyte samples, after stratifying by drug group. This
was carried out by calculating the mean oocyst number on
midguts resulting from TYRG-positive feed samples and
comparing this to the mean oocyst number on midguts
resulting from feeds containing any other genotypes, and
producing a ratio of the means. In the same way, we then
compared oocyst burden in the 48 midguts for which four-
locus genotype data were available. Results of both analyses
are presented in Table 3.
The presence of TYRG in gametocyte samples and in
oocyst DNA was associated with a signiﬁcantly lower oocyst
burden from CQ-treated individuals. In the SP-treated group,
TYRG gametocytes also led to lower oocyst burdens, with
borderline signiﬁcance (p ¼ 0.051). However, after CQ/SP
treatment, parasites carrying TYRG resulted in signiﬁcantly
greater transmission success compared to other genotypes in
this treatment group.
DISCUSSION
Interpretation
When compared to the rapidly waning efﬁcacy of CQ
monotherapy in our study area [7], addition of SP to CQ
provided therapeutic efﬁcacy of over 90% after PCR
correction in both this trial in 2001, and in a trial carried
out 1 y later [11,15]. CQ/SP has been the recommended
treatment for uncomplicated malaria in the Gambia since
2004. SP alone has had a measured parasitological efﬁcacy of
approximately 90% over 28 d in the Gambia [15,19].
However, both SP and CQ/SP are characterized by substantial
rates of posttreatment gametocyte emergence [9,11], and
because alleles of pfdhfr and pfdhps associated with SP failure
are present in the Farafenni area, we expected that parasites
resistant to both drugs would be frequently transmitted
following combination treatment.
In this study, CQ/SP treatment was followed by little
reduction in posttreatment prevalence and density of
gametocytes, compared to CQ alone. Only at the day 28
follow-up point was gametocyte carriage in the CQ/SP-
treated group signiﬁcantly lower than in the CQ group.
However, gametocytes occurred more frequently and at
higher density in the SP group throughout posttreatment
follow-up and particularly at day 28 (Figure 3), suggesting that
CQ/SP-treated children may be infectious for a shorter
period of time following treatment than those treated with
SP alone. This may be the result of more rapid asexual
parasite clearance by CQ/SP [8], combined with the activity of
CQ against early developing gametocytes [6].
Gametocyte carriers from all three treatment groups were
infectious to A. gambiae in experimental feeding. Remarkably,
the high gametocyte densities observed among the SP-treated
group at day 7 in particular did not translate into substantial
infectiousness (Figure 3). Gametocyte carriers in the SP group
identiﬁed at day 10 or 14 were signiﬁcantly more infectious to
mosquitoes, suggesting that gametocytes circulating at day 7
after SP treatment, but not CQ or CQ/SP treatment, have not
attained sufﬁcient maturity to infect mosquitoes efﬁciently.
.......................................................................................................................................................................................
Table 3. Contribution to Transmission Success of Multilocus Resistant Genotypes in Gametocytes and Oocysts
Drug
Group
TYRG in Feed Sample Gametocytes TYRG in Midgut Oocysts
Mean Oocyst
Burden
Oocyst Ratio, TYRG
Genotype versus Others
(95% CI)
[Number Mosquitoes Dissected]
Mean Oocyst
Burden
Oocyst Ratio, TYRG
Genotype versus Others
(95% CI)
[Number Midguts Positive]
TYRG Other TYRG Other
CQ 0.095 1.06 0.090 (0.009–0.886)
p ¼ 0.039
[368]
2.00 30.80 0.065 (0.008–0.508)
p ¼ 0.009
[12]
CQþSP 4.03 0.081 49.4 (4.38–557)
p ¼ 0.002
[370]
36.85 3.75 9.83 (3.260–29.63)
p , 0.001
[18]
SP 0.067 0.27 0.249 (0.616–1.01)
p ¼ 0.051
[942]
6.58 13.67 0.482 (0.168–1.382)
p ¼ 0.174
[18]
Ratio of mean oocyst burden is calculated, and then p value is calculated by univariate negative binomial regression.
Statistically significant probabilities are shown in boldface.
DOI: 10.1371/journal.pctr.0010015.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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One explanation for this observation is that, because SP
appears unable to kill even the earliest developing gametocyte
stages sequestered in the host tissues at the time of treatment
[9], many of the emergent gametocytes seen on day 7 are not as
yet fully mature, although morphologically they appear so. In
contrast, CQ will kill genotypically sensitive gametocytes in the
early stages of development, and so day 7 emergent game-
tocytes are those that were already some way to maturity at the
time of treatment. However, this does not explain why the
signiﬁcant numbers of CQ-resistant parasites were not also less
infectious at day 7 in the CQ treatment group, because their
early development is expected to be unimpaired by drug. An
alternative hypothesis is that SP treatment in some way
perturbs the gametocyte sex ratio, so that the accumulation
of one sex is delayed, thus preventing fertilization until
sufﬁcient of both sexes are present in the gametocyte
population.Itremainsunclearwhythematurityofgametocytes
was a particularly important factor in the infectiousness of
children who had also harboured gametocytes at day 0.
Resistance-associated alleles at ﬁve of the seven loci
examined were more common among gametocyte carriers
than among noncarriers in a randomly selected group of
pretreatment isolates, as was the pfdhfr ‘‘triple mutant’’
haplotype of 51-I, 59-R, and 108-N (Figure 4). The multilocus
genotype TYRG (pfcrt-76T, pfmdr1-86Y, pfdhfr-59R, and pfdhps-
437G) was also more common among gametocyte carriers, and
amongchildrendonatinggametocytesforfeedingexperiments,
than among noncarriers, although this was not statistically
signiﬁcant. In the accompanying paper, the TYRG genotype
was found to be weakly associated with parasitological failure
after SP treatment, but not after CQ/SP treatment [15].
The presence of the TYRG multilocus genotype among
either gametocytes membrane-fed to mosquitoes, or among
P. falciparum oocysts present in infected mosquito midguts was
associated with signiﬁcantly higher oocyst burdens in the CQ/
SP combination group. This was independent of feed type or
the presence of gametocytes prior to treatment, and was
much stronger than the association between this genotype
and treatment failure [15]. TYRG carrying parasites thus
appear to enjoy a substantial survival advantage, which leads
to favourable transmission under CQ/SP treatment. In
contrast, TYRG genotypes were less successfully transmitted
than other genotypes in both monotherapy arms; in the CQ
treatment group, this difference was statistically signiﬁcant.
This supports the view that drug-resistant parasites are likely
to be less ﬁt, relative to other genotypes in the population, in
the absence of the particular drug or combination of drugs
that has led to their selection [20].
Generalizability
Our data did not provide clear evidence of within-host
selection for the TYRG genotype, as we have previously
observed in CQ-treated patients [12,13]. This is probably due
to the fact that some of the alleles, particularly pfcrt-76T and
pfdhfr-108N, were at a high starting prevalence and so wild-
type alleles were rare.
Taken together, our analyses of therapeutic and trans-
mission endpoints of this clinical trial demonstrate that
multidrug-resistant parasites enjoyed a survival advantage in
terms of their likelihood of transmission to mosquitoes, but
that the particular genotypes encountered in the Gambia did
not threaten the therapeutic efﬁcacy of CQ/SP [11,15].
Pretreatment genotyping of 90 children in a subsequent trial
in 2002 [11] showed that pfdhfr and pfdhps mutation
prevalences remained stable (pfdhfr triple mutant present in
50 of 89 or 56.2%; 95% CI, 45.9–66.5; pfdhps 437G present in
39 of 79 or 49.4%; 95% CI, 38.4–60.4) (R. Hallett and C.
Sutherland, unpublished data). However, CQ monotherapy
remained ﬁrst line treatment at this time and CQ/SP was not
being commonly used. The apparent anomaly between the
widespread prevalence of the pfdhfr triple mutant in Africa
and its weak association with risk of treatment failure [21]
may simply be because its primary effect has been to enhance
transmission of parasites under SP drug pressure, and this has
been sufﬁcient to ensure its persistence and spread.
Overall Evidence
The work presented in this paper extends our previous
studies of CQ-treated, SP-treated, and CQ/SP-treated patients
in this study area [9–11,13]. There are no previous published
studies to our knowledge that measure transmission end-
points among African patients treated with CQ/SP. We have
shown that multidrug-resistant P. falciparum are prevalent in
West Africa and that transmission of these genotypes is
favoured when CQ and SP are combined for treatment of
uncomplicated malaria in children. Thus, evolution of
resistance to this combination will continue despite any
reduction in its therapeutic efﬁcacy, so far. These ﬁndings
demonstrate the importance of measuring transmission
endpoints in studies of the evolution of resistance to
antimalarial chemotherapy.
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